The early decline and recovery of retinal structure and function following iatrogenic macular detachment for retinal gene therapy is not well characterized in those with relatively preserved central visual function. Here, the recovery of retinal structure and function over the first month following iatrogenic retinal detachment for the delivery of adeno-associated viral vector encoding Rab Escort Protein 1 is described as a part of gene therapy for choroideremia.
R etinal detachment occurs as the result of pathological processes that are broadly classified by their etiology into exudative, tractional, or rhegmatogenous forms. Deliberate iatrogenic detachment represents a unique etiological mechanism; its use reached an initial zenith more than a decade ago in the surgical management of choroidal neovascular membranes. 1 More recently, limited iatrogenic detachment has been used in retinal gene therapy. [2] [3] [4] This maneuver appears to only rarely compromise retinal function, 5 and no cases of proliferative vitreoretinopathy (PVR)-a known complication of more invasive procedures, such as retinal translocation and retinal pigment epithelium (RPE) transplantation 1 -have been reported. However, such observations come with caveats. First, any visual decline produced by iatrogenic detachment may be defrayed by improvements resulting from successful retinal transduction. Second, an asymptomatic retinal hole has been reported in 1 patient with Leber congenital amaurosis (LCA) following iatrogenic detachment. 3 Third, central retinal atrophy is noted in approximately 50% of patients with LCA following iatrogenic detachment as part of gene therapy. 6, 7 Other forms of macula involving retinal detachment are, as a rule, associated with declines in spatial, 8 temporal, 9 and spectral resolution. 8 The effects on visual function of the most common cause of limited detachment of the macula-central serous retinopathyhave been studied in detail. 10, 11 Although best-corrected visual acuity (BCVA) may be unaltered in central serous retinopathy, patients commonly exhibit acquired tritan colorvision deficiency combined with a red-shifted and widened Rayleigh match known as pseudoprotanomaly. 10, 11 The latter is the result of reduced cone photopigment optical density, possibly through altered outer-segment alignment.
11
There is limited histological evidence of the effects of iatrogenic macular detachment on photoreceptor structure. Simian models demonstrate cone outer-segment shortening after extensive iatrogenic detachment that resolves after 5 months. 12 However, experiments involving limited retinal detachment as part of RPE transplantation procedures in humans suggest that M-and L-cone outer segments are not discernably affected. 1 Recent analysis of spectral domain optical coherence tomographic (OCT) scans has demonstrated that disruption and thinning of the retina follow macula-off rhegmatogenous retinal detachment. This largely resolves, with a small but statistically significant residual thinning of the RPE to ellipsoid zone distance observed at 12 months. 13 This lengthy period of retinal remodeling mirrors the natural history of functional recovery. 8 It should be noted that the height of macula-off detachment has been demonstrated to correlate with final visual acuity following reattachment. 14, 15 A further issue is the duration of detachment, which has been demonstrated in natural history studies to correlate with loss of function. 15, 16 These combined observations may explain the differences in findings between simian and human histopathological studies.
Retinal gene therapy for choroideremia necessitates iatrogenic retinal detachment in patients with well-preserved central vision. Given the evidence for the deleterious effects of retinal detachment, we aimed to study changes in both retinal structure and function during the first month following surgery.
Methods
The male participants included in this study were the final 5 consecutively treated patients in a phase 1/2 clinical trial of gene therapy for choroideremia (clinicaltrials.gov identifier NCT01461213). 4 This study was approved by the National Re- Meaning Retinal structure and function appears to recover rapidly following iatrogenic macular detachment.
match in which the patient must match a mixture of green light (545 nm) and red light (679 nm) to monochromatic yellow light (589 nm). 18 The Neitz anomaloscope presents the Rayleigh match as a circular bipartite 2°field viewed through a Keplerian eyepiece: The top half of the circular field is the green-red mixture and the bottom half is monochromatic yellow. As described by Smith and colleagues, 11 results were expressed as the log 10 of the anomalquotient (AQ):
where G p is the green setting at the midmatching point of the patient, R p is the red setting, and G n and R n are the green and red settings at the midmatching points of healthy patients (normal log 10 A Q=0±0 .2 ) .A l lk e ynumerical variables were averaged across patients and expressed as means with standard errors (SEs).
Retinal structure was assessed using Heidelberg SPECTRALIS spectral domain OCT (Heidelberg Engineering GmbH) in accordance with the manufacturer's protocols. A 5-line horizontal raster and "dense volume" fovea-centered OCT images were assessed for the presence of subretinal fluid at 1 day, 1 week, and 1 month following surgery. In addition, we measured changes in retinal thickness. Baseline outer-retinal degeneration in choroideremia precluded accurate assessments of RPE-ellipsoid zone thickness. Instead, we measured total central foveal thickness and average retinal thickness in the central 1 mm 2 . Central foveal thickness estimates were obtained after locating the foveal center of the baseline scans. This point was marked using the Heidelberg Eye Explorer software (Heidelberg Engineering) such that the same position could be assessed in subsequent scans. Measurements were made using ×400 zoom and the built-in caliper function. In addition, we measured average retinal thickness within the central 1 mm 2 after first checking and, where appropriate, modifying manually the segmentation of acquired images. In each instance, the retinal thickness was measured from the internal aspect of the internal limiting membrane to the outer border of the RPEBruch's membrane complex. Each patient underwent unilateral gene therapy treatment with the fellow eye acting as an internal control. The gene therapy procedure was undertaken by a single surgeon (R.E.M.) following a standard 3-port 23-gauge trans pars plana vitrectomy (Alcon Accurus System). Subretinal gene therapy occurred as a 2-step procedure. 4 In the first step, a subretinal bleb of approximately 6 disc areas and which included the fovea was raised by injecting balanced salt solution through a 41 G Teflon, blunt-tipped cannula (DORC) at a maximal pressure of 12 psi from the viscous fluid controller port of the vitrectomy system. The retinotomy site was always superior to the macula and at the edge of an island of well-preserved retina and RPE to aid in the process of finding and defining the correct surgical plane. 4 In the second step, 0.1 mL of an adeno-associated Recovery of structure following iatrogenic detachment. The iatrogenic retinal detachment was resolved by day 1 following treatment.
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Recovery Following Limited Iatrogenic Macular Detachment for Retinal Gene Therapy viral particles was injected into the bleb through the same retinotomy. 4 (Note that the treatment dose in this extension study is 1 log-unit higher than previously reported.) The eye was left with balanced salt solution as a vitreous substitute at the completion of intraocular surgery, and the sclerostomies were closed with 8-0 polyglactin 810 sutures. In 1 patient (patient 10), the surgical procedure was modified because of the presence of a thin fovea. In this patient, the subretinal bleb was raised around the fovea while a small bubble of n-perfluoro-octane protected the thinned fovea from stretch, maneuvers similar to those described previously. 21 After n-perfluoro-octane aspiration, the subretinal fluid containing the vector suspension was observed to have extended passively subfoveally. This patient also underwent partial fluid-air exchange at case completion to protect the fovea from opening into a macular hole.
Results
Five white male patients aged 23 to 71 years underwent unilateral subretinal gene therapy for genetically confirmed choroidermeia (eTable in the Supplement). All 5 patients (patients 10-14) underwent successful surgery, with the macula being detached by subretinal balanced salt solution and AAV.REP1 vector at the completion of surgery. Optical coherence tomographic images could be obtained for only 4 patients at day 1 (as patient 10 had air as the initial vitreous substitute following surgery). These images demonstrated resolution of the subretinal fluid; furthermore, no evidence of fluid reaccumulation was noted in any of the patients at 1 week or at 1 month (Figure 1) . In contrast to the OCT changes observed in patients with rhegmatogenous . Although patient 13 appeared to have improved visual acuity in the control eye following treatment, his visual acuities at baseline with this eye were variable because of his variable fixation strategy given his poor visual acuity. Because this was his worse eye, it had originally been scheduled to undergo gene therapy; however, at the baseline visit, he was unable to read the required chart line to meet the entry criterion (20/200) with his right eye despite having read the same line several times previously. After lengthy discussion and counseling, he agreed to proceed with treatment to his better (left) eye, which had stable BCVA and which met the criterion for treatment. The apparent improvement in visual acuity in the control eye, therefore, reflects the variability in his fixation strategy in this eye and his 1-week and 1-month acuities are similar to the estimates leading up to the trial. Two of 5 patients were able to perform the Rayleigh matches; the remaining patients were unable to perform matches because of difficulties in maintaining alignment with the Keplerian eyepiece due to their limited visual field. In patient 12, no shift in Rayleigh match was noted at either 1 week or 1 month, although his baseline matches were consistent with a diagnosis of congenital protanomaly (a congenital color-vision deficiency affecting about 1% of the male European population). 23 In patient 10, pseudoprotanomaly was noted at 1 week but showed signs of partial resolution at 1 month ( Figure 5 ).
Discussion
Previous descriptions of visual recovery following iatrogenic retinal detachment for the delivery of subretinal gene therapy have chiefly concentrated on medium-to long-term visual scribes the short-term recovery of retinal structure and function in patients with comparatively well-preserved central retinal architecture and central visual function.
As anticipated, we observed a total resolution of subretinal fluid in all patients by 1 week. Although we cannot definitively exclude some regurgitation of subretinal fluid via the 41 G retinotomy site, the supposition is that resolution occurs actively through other routes, particularly because small subretinal air bubbles are likely to prevent egress of subretinal fluid through superiorly placed retinotomies. In the healthy eye, extensive bullous retinal detachments commonly resolve within several hours via RPE-facilitated choroidal drainage in patients treated with pneumatic retinopexy. Although patients with choroideremia have loss of peripheral RPE, this mechanism in the central residual chorioretinal island may be sufficient to reabsorb the small volumes of subretinal fluid delivered in the process of gene therapy. Alternative routes in our patients could also include reabsorption through the retina or the scleral vasculature.
In contrast to macula-off rhegmatogenous retinal detachment, where significant thinning is observed, 13 the effects of the iatrogenic detachment procedure on OCT appearance are minimal in the early postoperative period. Several reasons may account for this observation. First, the patients with choroideremia had baseline alterations in central retinal structure that may have masked alterations due to iatrogenic macular detachment. Second, the limited iatrogenic macular detachments resulted in minimal retinal elevation: Natural history studies suggest that the negative effect of macular detachment correlates with detachment height. 14 Third, the iatrogenic macular detachment resolved overnight: Natural history studies suggest that the negative effects of macula-off detachments correlate with their duration. 24 The fact that other In keeping with our previous observations, visual acuity returned to, or improved over, baseline levels within 1 month of treatment. Color discrimination at the FM 100-hue similarly recovered to baseline by 1 month in 2 of the 4 patients tested. In 1 patient (patient 13), an overall improvement in error score was noted at 1 month in the treated eye; this improvement was accompanied by a subjective increase in saturation of colors. However, in the remaining patient (patient 10), an exacerbation of a type III, acquired tritan color-vision deficiency was noted at the FM 100-hue test undertaken at 1 month; this was accompanied by pseudoprotanomaly at 1 week and 1 month. The shift in Rayleigh match at 1 week is equivalent to a loss of 50% to 60% in cone photopigment optical density, 25 and there are several possible explanations for this observation. One possibility is photoreceptor misalignment, which has been proposed to account for the pseudoprotanomaly observed in central serous retinopathy. 11 However, given that directional photoentrainment may occur over 5da ys 26 to 3 weeks, 27 photoreceptor misalignment may not solely account for the effect observed in patient 10, unless we suppose that the detachment procedure or the disease itself has had a negative effect on this process. It is also possible that this patient's pseudoprotanomaly resulted from a decrease in photopigment concentration, decreased outer-segment length, or both. Given previous histological observations of retinal detachment in simian models, 12 combined with the OCT observations of natural history studies of patients with macula-off rhegmatogenous detachment, 13 it is likely that alterations in cone outer-segment length may play a role. Baseline retinal changes made it impossible for us to accurately determine if the RPE-ellipsoid zone distance has decreased following surgery, although patient 10 was the only patient in whom central foveal thickness decreased at 1 month. Regardless of the mechanism of pseudoprotanomaly in patient 10, our findings suggest that color discrimination and color matching may provide a suitable means of tracking subtle changes in retinal function caused by subretinal injections in patients with wellpreserved central vision.
Limitations
Our study had limitations. Although our patient group demonstrated rapid structural and functional recovery following iatrogenic macular detachment, it is unknown whether similar recovery would occur in patients with other inherited retinal diseases. However, given that we anticipate mildly dys- 
